

Roberta Gagliardini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5435259/publications.pdf>

Version: 2024-02-01

24
papers

378
citations

758635

12
h-index

794141

19
g-index

24
all docs

24
docs citations

24
times ranked

748
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy113.	0.4	56
2	Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv043.	0.4	30
3	Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1955-1964.	1.3	29
4	Role of testosterone in SARS-CoV-2 infection: A key pathogenic factor and a biomarker for severe pneumonia. <i>International Journal of Infectious Diseases</i> , 2021, 108, 244-251.	1.5	29
5	Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2055-2059.	1.3	28
6	Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study. <i>Antiviral Research</i> , 2019, 169, 104552.	1.9	23
7	Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice. <i>BMC Infectious Diseases</i> , 2019, 19, 59.	1.3	23
8	Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital. <i>International Journal of Infectious Diseases</i> , 2021, 105, 532-539.	1.5	20
9	Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE). <i>Clinical Neuropsychologist</i> , 2016, 30, 1457-1468.	1.5	19
10	GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults. <i>Science Translational Medicine</i> , 2022, 14, eabj1996.	5.8	18
11	Liver fibrosis progression and clinical outcomes are intertwined. <i>Medicine (United States)</i> , 2016, 95, e4091.	0.4	17
12	Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-term all-cause mortality: a MASTER cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3519-3527.	1.3	16
13	Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106252.	1.1	13
14	Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. <i>PLoS ONE</i> , 2017, 12, e0187393.	1.1	11
15	Predicting respiratory failure in patients infected by SARS-CoV-2 by admission sex-specific biomarkers. <i>Biology of Sex Differences</i> , 2021, 12, 63.	1.8	10
16	3-Year Efficacy and Durability of Simplification to Single Tablet Regimens: A Comparison between Co-Formulated Efavirenz/Emtricitabine/Tenofovir and Rilpivirine/Emtricitabine/Tenofovir. <i>Antiviral Therapy</i> , 2018, 23, 139-148.	0.6	9
17	Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice. <i>Journal of Global Antimicrobial Resistance</i> , 2022, 30, 326-334.	0.9	6
18	Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients. <i>Journal of Chemotherapy</i> , 2017, 29, 299-307.	0.7	5

#	ARTICLE	IF	CITATIONS
19	Liver fibrosis is associated with cognitive impairment in people living with HIV. <i>Infection</i> , 2019, 47, 589-593.	2.3	4
20	Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106406.	1.1	4
21	HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART. <i>Journal of Clinical Virology</i> , 2018, 103, 57-62.	1.6	3
22	The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, e17-e21.	0.9	2
23	Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study. <i>Journal of Global Antimicrobial Resistance</i> , 2022, , .	0.9	2
24	Ophthalmic artery resistance index is increased in HIV-Infected patients and is influenced by protease inhibitors exposure. <i>Journal of Infection</i> , 2014, 68, 500-503.	1.7	1